AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyNot reportedTrial registry
Human Phase 1/2 Study on PF-08154225 in Autoimmune Diseases
A Phase 1/2 study of PF-08154225 aimed at evaluating its safety and tolerability for autoimmune diseases has not yet begun recruiting participants and is not expected to finish until 2031.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
This study could eventually provide insights into potential safety and adverse events related to PF-08154225 in conditions like systemic lupus erythematosus and rheumatoid arthritis, but no data exists at this point.
What this does not prove
No results have been reported as this trial has not yet begun recruitment. This study is still in the planning phase, with anticipated endpoints yet to be assessed.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
Supporting passages (5)
peer reviewedNo results are posted.
primary endpoint"measure": "Incidence and severity of Treatment Emergent Adverse Event (AE) including protocol specified adverse event of special interest(AESI)",
findings"overallStatus": "NOT_YET_RECRUITING",
subjects"officialTitle": "A PHASE 1/2, MULTI-CENTER, OPEN-LABEL, SINGLE- AND MULTIPLE-DOSEESCALATION, DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY EFFICACY OF PF-08154225, IN PARTICIPANTS WITH AUTOIMMUNE DISEASES INCLUDING ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), OR RHEUMATOID ARTHRITIS (RA), OR IDIOPATHIC INFLAMMATORY MYOSITIS (IIM) OR SYSTEMIC SCLEROSIS (SSC)"
limitationsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.